Bayer Extends Its Reach in Cancer, Immunology Research with Vividion Purchase

In the latest in a series of acquisitions aimed at quickly ramping up its portfolio of new drugs, Bayer is acquiring San Diego, Calif.-based biopharmaceutical firm Vividion Therapeutics in a deal worth up to $2 billion.

Vividion, which develops precision drugs for treatment of cancers and immune disorders, expects to file its first investigational new drug application in 2022.

The purchase agreement includes a $1.5 billion upfront payment plus potential future milestone payments of up to $500 million.